MAPT and Alzheimer disease: Hence, the confounding effects of other brain pathologies associated with increased p-Tau and/or t-Tau levels (such as cerebrovascular changes, Lewy bodies, etc.)are minimized in ADNI, so that the role of Aβ42 as an indicator of AD pathophysiology may be exaggerated.